

Keynote lecture

MITRAL REGURGITATION AND TAKOTSUBO: A DANGEROUS LIASON


Rodolfo Citro MD PhD FESC

Professor of Cardiology - University of Molise Dir. U.O.C Cardiology Clinic and Cardiac Imaging **Responsible Research Hospital**

Campobasso (Italy)

34 years since original description of Takotsubo Syndrome by Sato

Sato H, Tateishi H, Uchida T, Dote K, Ishihara M. Tako-tsubo-like left ventricular dysfunction due to multivessel coronary spasm. In: Kodama K, Haze K, Hori M, editors. Clinical aspect of myocardial injury: from ischemia to heart failure. Tokyo: Kagakuhyoronsha Publishing Co.; 1990. p. 56–64. (in Japanese)






Figure 2. The left ventriculography of Case 1 at admission (left) and a week later (right) The left ventricle had a unique "Takotsubo shape" and it disappeared after a week.

Thanks to Birke Schneider

Why 'Takotsubo'? First described in Hiroshima, Japan 1990





蛸壺

蛸 (tako) means octopus, the left-hand side of the character (虫) is the "insect/worm/ snake/reptile/shellfish radical"; (肖) is originally composed of 小 "small" and 肉 "flesh," so the character could be sourced to meaning: "small fleshy, reptile-like animal."


壺 (tsubo) means "pot," and may be combined, for example, with the character "tea" 茶 to form the word tea-urn in Japanese or teapot in Chinese (茶壺). Its lower, hollow cross-shaped part (亞) represents the bulging section of a pot, the upper part (士) represents the lid.





Evidence Pyramid in Takotsubo Syndrome





 $\mathsf{EHR} = \mathsf{electronic} \ \mathsf{health} \ \mathsf{records}; \ \mathsf{RCT} = \mathsf{randomized} \ \mathsf{clinical} \ \mathsf{trial}; \ \mathsf{TTS} = \mathsf{Takotsubo} \ \mathsf{syndrome}.$



Weaknesses (the above not)

Difficult to be realized, especially in the context of rare disease

Follow-up data may be depleted of clinical significance

Possible selection bias

Possible reduced data quality and absence of data monitoring

Lowest evidence power

Citro R, Bellino M, Silverio A JACC ADVANCES 2023



Multimodality imaging in takotsubo syndrome: a joint consensus document of the European **Association of Cardiovascular Imaging (EACVI)** and the Japanese Society of Echocardiography (JSE)

Rodolfo Citro (Chair)¹*, Hiroyuki Okura (Co-Chair)², Jelena R. Ghadri³, Chisato Izumi⁴, Patrick Meimoun⁵, Masaki Izumo⁶, Dana Dawson⁷, Shuichiro Kaji⁸, Ingo Eitel^{9,10}, Nobuyuki Kagiyama¹¹, Yukari Kobayashi¹², Christian Templin³, Victoria Delgado¹³, Satoshi Nakatani¹⁴, and Bogdan A. Popescu^{15,16}


EACVI CONSENSUS DOCUMENT




Dr. Hiroyuki Okura **Dr. Rodolfo** Citro

MMI in TTS diagnosis


POCUS for diagnostic suspect of TTS **#echofirst**



Acute phase



Post-acute phase



syndrome

LV WMAs

RV involvement

Speckle-tracking

Coronary flow


EF, ejection fraction; LV, left ventricular; RV, right ventricular; TTS, takotsubo syndrome; WMAs, wall motion abnormalities.

Table 3 Main echocardiographic findings in takotsubo

- LV systolic function Marked reduction in LVEF on admission with improvement at short term
 - Independent of the distribution of epicardial coronary artery (circumferential pattern)
 - Apical ballooning
 - Variant form: mid-ventricular ballooning; inverted TTS
 - Reverse McConnell sign (biventricular ballooning)
 - Circumferential impairment of LV longitudinal and radial strain
 - Preserved distally to the coronary artery
 - Coronary flow reserve is impaired in the acute phase



Prevalence of complications in TTS in INTER-TAK registry



Tachyarrhythmia (2-5%) Bradyarrythmia (2-5%) Torsades des Pointes (2-5%) Death (1-4.5%) Ventricular tachycardia/fibrillation ~3% Acute ventricular septal defect <1%

Atrial Fibrillation (5-15%) LV-Thrombus (2-8%) Cardiac Arrest (4-6%) AV-Block ~5%

Acute Heart Failure (12-45%) LVOTO (20-25%) Mitral Regurgitation (14-25%) Cardiogenic Shock (6-20%)

/ E RAL CARDIOMYOPATHIES **NH PALERMO** Left Ventricular Apical Ballooning Syndrome as a Novel Cause of Acute Mitral Regurgitation

Baseline Clinical and Echographic Characteristics of Patients With and Without Significant Acute Mitral Regurgitation

Variable	Overall Study Group (n = 68)	Patients With Acute Mitral Regurgitation (n = 14)	Patients Without Acute Mitral Regurgitation (n = 54)	p Value		
Age (yrs)	74 ± 10	76 ± 7	74 ± 10	0.349		
Female	64 (94%)	14 (100%)	50 (93%)	0.294		
ypertension	39 (57%)	8 (57%)	31 (57%)	0.986		
liabetes mellitus	7 (10%)	1 (7%)	6 (11% Case # 1	CONTRACTOR OF	Ca	se # 9
ypercholesterolemia	26 (38%)	4 (29%)	22 (41%)			
moker	14 (21%)	3 (21%)	11 (20%)			
Intecedent stressful event*	49 (72%)	9 (64%)	40 (74%)			
ystolic blood pressure (mm Hg)	122 ± 24	113 ± 22	124 ± 24			
iastolic blood pressure (mm Hg)	71 ± 14	67 ± 16	71 ± 14		100 - 200 No. 100	
eart rate (beats/min)	89 ± 19	93 ± 18	88 ± 20			
T-segment elevation	51 (75%)	11 (79%)	40 (74%)		And the second	
illip class III or IV	14 (21%)	7 (50%)	7 (13%)	LA		LA
reatine kinase-MB peak (U/I)	28 ± 43	57 ± 83	21 ± 33		LV	
ime to peak creatine kinase (h)	5 ± 6	5 ± 5	5 ± 6		A CONTRACTOR OF	LV
tra-aortic balloon pump use	9 (13%)	5 (36%)	4 (7%)			
alcium channel blockers at discharge	10 (15%)	0	10 (19%)		STATISTICS NO.	
eta-blockers at discharge	37 (54%)	9 (64%)	28 (52%)			
CE inhibitors or angiotensin receptor blockers at discharge	53 (78%)	10 (71%)	43 (80%)			
V internal diameter (mm)	46 ± 5	47 ± 5	46 ± 5			
F on admission (%)	33 ± 9	26 ± 7	35 ± 9	0.001		
F at discharge (%)	49 ± 10	41 ± 11	52 ± 9	0.001		
VEF >50% at discharge	36 (53%)	3 (21%)	33 (61%)	0.008		
Time to FE >50% (days)	7 + 4	9+4	7 + 4	0.057		
Mitral SAM	7 (10%)	5 (36%)	2 (4%)	<0.0001		
With mitral-septal contact	4 (6%)	3 (21%)	1 (2%)	0.045		
Mitral regurgitation grade	1.4 ± 1.1	3.1 ± 0.5	0.9 ± 0.7	<0.0001	Par	odi G, et al. JACC 200



OCTOBER 24&25 2024




58 years old post-menopausal woman


No risk factors for CAD Mood disorder

Admitted in the ER of our Hospital for retrosternal chest pain


(Of note she reported the onset of chest pain immediately after the scare for risking a road crash with her car)



ECG



ECG anterior ST elevation



FAST ECHO: akinesia of the LV apical segments




Tnl: 0,4 ng/ml

Code: anterior STEMI


- Medical treatment
- •Enoxaparina,
- •ASA,
- ticagrelor and
- atorvastatin




•,,,,,,,in cath-lab to perform urgent coronary angiography




Coronary Angiography








VENTRICULOGRAPHY





Takotsubo syndrome





CCU admission

Patient developed dyspnea and profuse sweating

Heart: pansystolic murmur at the apex Chest: mid-basal pulmonary rales

BNP: 867 pg/ml

AP = 88/56 mmHg HR = 91/min $SpO_2 = 81\%;$ $pO_2 = 66$ mmHg $pCO_2 = 17$ mmHg pH 7,54


















1	Vmax
	Vmedi
	Pmax
	Pmean
	Env.T
	VTI
	HR




•EF = 40%

•Akinesia of the LV apex •Hyperkinesia oh the LV **basal segments**

PW Doppler evidence of flow in distal LAD



Severe functional MR







EUROVALVE & structural cardiomyopathies NH PALERMO




LVOTO


Vmax = 3.89 m/sec Intraventricular gradient = 60.52 mmHg



OCTOBER 24&25 2024







Color M-mode of LVOT showing systolic aliasing



Cardiogenic shock patient with takotsubo syndrome complicated by LVOTO and mitral regurgitation



How do you treat?

a) Levosimendan + loop diuretic

b) Inotropic agents + loop diuretic


c) Intraortic balloon pump + loop diuretic

d) Metoprolol + loop diuretic

e) Esmolol followed by metoprolol + loop diuretic




The day after...TTE



Mild MR



EUROVALVE & structural cardiomyopathies NH PALERMO




The day after...TTE

Vmax = 1.99 m/sec Grad Max = 15.79 mmHg



OCTOBER 24&25 2024






No evidence of aliasing at Color M-mode of LVOT

EUROVALVE & structural cardiomyopathies NH PALERMO

At 1 month follow up...













TTE GLS = -23.6%

At 1 month follow up... $\bullet EF = 62\%$ No evidence of WMA











At 1 month follow up... TTE






Mild MR






During catheterization, the patient was restless, cold, clammy, and with severe systemic hypotension (70/40 mmHg).

Owing to the blood desaturation to 82%, oxygen therapy delivered by facemask was promptly started.




Intraventricular pressure gradient (Peak gradient of 71 mmHg)




Severe MR



Owing to the persistence of a poor hemodynamic condition, an Impella CP® assist device (Abiomed, Danvers, Massachusetts) was placed throught the right femoral artery










The hemodynamic status promptly improved (blood pressure increased to 95/60 mmHg) and oxygen saturation raised to 93%.




EUROVALVE **STRUCTURAL CARDIOMYOPATHIES NH PALERMO**

Clinical case

The patient was transferred to the cardiac care unit (CCU) where she was maintained on adequate hydration, low dose (0.1 µg/kg/min) noradrenalin infusion and Impella support.

the next two days, the patient's clinical status further improved and she was successfully titrated off vasopressorsOver


LV EF: 40%







However, LVOTO persisted at the attempt to wean off the patient from the Impella assistance






Clinical case At day 5, TTE showed a further improvement of LV EF (50%) and the disappearance of the dynamic LVOTO during prolonged standby of the mechanical circulatory support (MCS). Impella was removed.

The patient was discharged after one week in stable hemodynamic and clinical conditions with beta-blockers and ACE inhibitor. BNP was 360 pg/ml.

At one month, TTE confirmed the complete recovery of WMA and LV systolic function (LV EF: 60%), mild MR and absence of LVOTO.









Impella in unstable TTS patient with LVOTO

Early MCS with Impella may provide a reasonable therapeutic approach in patients with cardiogenic shock due to TTS complicated by LVOTO and severe MR.

The Impella device, by propelling blood from the LV into the ascending aorta, allows skipping the LVOTO and the maintenance of the systemic pressure.

This benefit may be observed after implantation as well as during CCU course, before LV function recovery and LVOTO disappearance (bridge-to-recovery).



227 pts Major adverse events in 59 pts

Table 5. Hazard ratio (95% CI) for the major adverse events (acute heart failure, cardiogenic shock, and inhospital mortality) in univariate and multivariate models.

Variables	Wald Chi- square	P-value	HR	95% CI	Wald Chi- square	P-value	HR	95% CI
Age ≥ 75	7.162	0.007	2.353	1.257-4.403	4.270	0.039	2.818	1.055-7.529
Heart rate	4.492	0.034	1.020	1.001-1.038				
Chest pain with dyspnea	9.552	0.002	3.477	1.578-7.664				
BNP	3.385	0.049	1.002	1.000-1.004				
LVEF	15.398	< 0.001	0.892	0.842-0.944	18.400	< 0.001	0.923	0.890-0.958
E/e' ratio	23.345	< 0.001	1.266	1.150-1.393	6.410	0.011	1.131	1.028-1.244
sPAP	23.549	< 0.001	1.086	1.050-1.122				
Moderate to severe MR	23.532	< 0.001	5.916	2.885-12.133	5.049	0.025	3.254	1.163-9.109
RV involvement	11.957	0.001	3.845	1.792-8.250				
LVOT obstruction	7.992	0.005	3.173	1.425-7.067				

BNP: brain natriuretic peptide; LVEF: left ventricular ejection fraction; LVOT: left ventricular outflow tract; MR: mitral regurgitation; RV: right ventricular; sPAP: pulmonary artery systolic pressure.



OCTOBER 24&25 2024




ORIGINAL RESEARCH

Echocardiographic Correlates of Acute Heart Failure, Cardiogenic Shock, and In-Hospital Mortality in Tako-Tsubo Cardiomyopathy

Rodolfo Citro, MD,*† Fausto Rigo, MD,† Antonello D'Andrea, MD,§ Quirino Ciampi, MD, Guido Parodi, MD, Gennaro Provenza, MD, # Raffaele Piccolo, MD, ** Marco Mirra, MD, †† Concetta Zito, MD, 11 Roberta Giudice, MD, 11 Marco Mariano Patella, MD, 88 Francesco Antonini-Canterin, MD, |||| Eduardo Bossone, MD, † Federico Piscione, MD, †† Jorge Salemo-Uriarte, MD,* on behalf of the Tako-Tsubo Italian Network Investigators

Citro R, et al. J Am Coll Cardiol Img 2014;7:119–29






Echocardiography in TTS: additive incremental prognostic value


CLINICAL AND ECHOCARDIOGRAPHIC CORRELATES OF ACUTE HEART FAILURE, CARDIOGENIC SHOCK AND IN-HOSPITAL MORTALITY IN TAKO-TSUBO CARDIOMYOPATHY

Citro R, et al. JACC Imaging. Feb 2014



EDITORIAL COMMENT









Figure 1. Mechanisms Postulated as Potential Components of Pathogenesis of Hypotension/Shock in TTC

Role of Echocardiography in Tako-Tsubo Cardiomyopathy

I(HONS), PHD, Thanh H. Nguyen, MD, MMEDSCI, PHD



TTS: Reversible moderate to severe MR



Variables	Overall population (n = 227)	Patients with major complications
		(n=59)
Moderate to severe MR	49 (21.5)	29 (49.1)



Recovery

 Patients without
 P value

 major
 complications

 (n=168)
 20 (11.9)

 20 (11.9)
 <0.001</td>

 Citro R, et al. JACC Imaging. Feb 2014

RV


RA



LVOTO: mechanisms

Small LV cavity

Septal buldge




LVOTO may result from basal LV hypercontractility, as occurs in the typical apical ballooning forms of TTS. Small left ventricles and septal bulge are predisposing factors.






Systolic Anterior Motion Begins at Low Outflow Tract Velocity

The pushing force of flow



The protruding leaflets extend into the edge of the flowstream and are swept by the pushing force of flow toward the septum. Flow pushes the underside of the leaflets



Sherrid et al. J Am Coll Cardiol 2000





Journal of Clinical Medicine



Dynamic Left Intraventricular Obstruction Phenotype in Takotsubo Syndrome

Davide Di Vece¹, Angelo Silverio², Michele Bellino², Gennaro Galasso², Carmine Vecchione^{2,3}, Giovanni La Canna⁴ and Rodolfo Citro^{2,5,*,†}








Journal of the American Heart Association

CONTEMPORARY REVIEW

Obstructive Hypertrophic Cardiomyopathy and Takotsubo Syndrome: How to Deal With Left Ventricular Ballooning?

Rodolfo Citro (), MD, PhD; Michele Bellino (), MD; Elisa Merli (), MD, PhD; Davide Di Vece, MD; Mark V. Sherrid (), MD




o mitral–s fterload r	high LVOTO septal contact, mismatch, mand ischemia
НСМ	
ļ	Recovery
	Normal LV systolic function, septal hypertrophy, abnormal mitral valve.
	Follow as HCM

Mechanisms of Acute Mitral Regurgitation in Patients With Takotsubo Cardiomyopathy An Echocardiographic Study

Masaki Izumo, MD, PhD; Smruti Nalawadi, MD; Maiko Shiota, MD; Jayanta Das, MD; Suhail Dohad, MD; Eiji Kuwahara, MD, PhD; Yoko Fukuoka, MD; Robert J. Siegel, MD; Takahiro Shiota, MD, PhD

- **Background**—Recent studies have suggested acute mitral regurgitation (MR) as a potentially serious complication of takotsubo cardiomyopathy (TTC); however, the mechanism of acute MR in TTC remains unclear. The aim of this study was to elucidate the mechanisms of acute MR in patients with TTC.
- Methods and Results—Echocardiography was used to assess the mitral valve and left ventricular outflow tract (LVOT) pressure gradient in 47 patients with TTC confirmed by coronary angiography and left ventriculography. Mitral valve assessment included coaptation distance, tenting area at mid systole in the long-axis view, and systolic anterior motion of the mitral valve (SAM). Of the study patients, 12 (25.5%) had significant (moderate or severe) acute MR. In patients with acute MR versus those without acute MR, we found lower ejection fraction $(31.3\pm6.2\%)$ versus $41.5\pm10.6\%$, P=0.001) and higher systolic pulmonary artery pressure (49.3 \pm 7.4 versus 35.5 \pm 8.9 mm Hg, P<0.001). Moreover, 6 of the 12 patients with acute MR had SAM, with peak LVOT pressure gradient >20 mm Hg (average peak LVOT pressure gradient, 81.3±35.8 mm Hg). The remaining 6 patients with acute MR revealed significantly greater mitral valve coaptation distance (10.9 \pm 1.6 versus 7.8 \pm 1.4 mm, P<0.001) and tenting area (2.1 \pm 0.4 versus 0.95 \pm 0.25 cm², P < 0.001) than those without acute MR. A multivariate analysis revealed that SAM and tenting area were independent predictors of acute MR in patients with TTC (all P < 0.001).
- Conclusions—SAM and tethering of the mitral valve are independent mechanisms with differing pathophysiology that can lead to acute MR in patients with TTC. (Circ Cardiovasc Imaging. 2011;4:392-398.)

Key Words: cardiomyopathy ■ mitral valve insufficiency ■ echocardiography






TTS: Reversible moderate to severe MR

Severe MR at presentation

Apical displacement (tenting area)





OCTOBER 24&25 2024





Mild MR at follow-up

No tenting area at follow-up

Izumo M Circ Cardiovasc Imaging 2011



CONCLUSION

- Echocardiography should be systematically performed in TTS patients to identify whether MR is present as well as to assess its mechanism.
 - SAM and tethering of the mitral valve are independent mechanisms with different pathophysiology that can lead to acute MR in patients with TTS.
- Being acute MR in TTS reversible despite current guidelines recommend mitral valve surgery in symptomatic unstable patients with severe acute MR; aggressive medical treatment or MCS according to the different etiologic mechanism should be preferred